Research programme: wound healing therapeutics -Innocoll/TGR Biosciences

Drug Profile

Research programme: wound healing therapeutics -Innocoll/TGR Biosciences

Alternative Names: TGR-265

Latest Information Update: 23 Sep 2010

Price : $50

At a glance

  • Originator Innocoll; TGR BioSciences
  • Class
  • Mechanism of Action Collagen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Wounds

Most Recent Events

  • 23 Sep 2010 No development reported - Preclinical for Wounds in USA (Implant)
  • 23 Sep 2010 No development reported - Preclinical for Wounds in USA (Topical)
  • 12 Sep 2007 Preclinical trials in Wounds in USA (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top